Buy Fulvestrant Powder Selective Estrogen Receptor Degrader Drug for Breast Cancer Online
Fulvestrant Specification
Product Name: Fulvestrant
CAS: 129453-61-8
Standard: USP35
Natural/Synthetic: Synthetic
Level: Pharmaceutical grade
Content: 99%
Appearance: white powder
Packing: 10G/Aluminum foil bag
Category: Pharmaceutical Raw Materials
Industry: Pharmaceuticals
Field: Steroid anti-estrogen drugs
Deferred product: Fulvestrant injection
Use: Estrogen receptor-positive locally advanced or metastatic mammary glands that can be used after anti-estrogen adjuvant therapy or during treatment, or after menopause (including natural menopause and artificial menopause) in anti-estrogen therapy cancer.
Usage and dosage: 1. Adult females (including elderly women): The recommended dose is once a month, once 250mg. There is a lack of information on the safety and efficacy of Chinese patients at higher doses. 2. Children and Adolescents: Since the safety and effectiveness of this product in children and adolescents have not been determined, the use of this product in this age group is not recommended. 3. Patients with impaired renal function: For patients with mild-to-moderate renal impairment (creatinine clearance ≥ 30 ml/min), there is no need to adjust the dose.
What is Fulvestrant?
Fulvestrant is a medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine therapy.
Fulvestrant is given by injection into a muscle.
Fulvestrant Certificate of Analysis
| Product name |
Fulvestrant |
| CAS No. |
129453-61-8 |
Outer Packing |
10g/foil bag |
| Production date |
2017-10-22 |
Shelf life |
2019-10-18 |
| Standard adopted |
USP35 |
| Items of analysis |
Specification |
Results |
| Appearance |
A white to off-white crystalline powder |
Conforms |
| Identification |
1、IR IR should conform to the standard |
Conforms |
| Specific rotaion |
+108°~ +115° |
110.8° |
| 6-Keto Fulvestran |
≤0.1% |
0.05% |
| ∆6,7-Fulvestran |
≤0.1% |
0.08% |
| Fulvestrant sulfone |
≤0.2% |
0.11% |
| Fulvestrant extended |
≤0.3% |
0.08% |
| Fulvestrant sterol dimmer |
≤0.8% |
0.09% |
| Fulvestrant β-isomer |
≤0.1% |
0.06% |
| Any individual unspecified impurity |
≤0.1% |
0.03% |
| Total impurity |
≤1.0% |
0.7% |
| FulvestrantA |
42%~48% |
45.42% |
| FulvestrantB |
52%~58% |
54.58% |
| Residue on lgnition |
≤0.1% |
0.03% |
| Drying loss |
≤0.5% |
0.30% |
| Water |
≤0.5% |
0.26% |
| Assay |
98.0%~102% |
99.2% |
| Conclusion |
Qualified |
Fulvestrant Side Effects
Very common (occurring in more than 10% of people) adverse effects include nausea, injection site reactions, weakness, and elevated transaminases. Common (between 1% and 10%) adverse effects include urinary tract infections, hypersensitivity reactions, loss of appetite, headache, blood clots in veins, hot flushes, vomiting, diarrhea, elevated bilirubin, rashes, and back pain.
